Загрузка...
THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER
Prostate cancer initially responds to androgen-deprivation therapy, but most patients eventually develop a castration-resistant form of disease. Enzalutamid is the superselective inhibitor of the androgen receptor (AR), which blocks several stages of the AR signal path. The drug showed significant e...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Russo |
| Опубликовано: |
Remedium Group LLC
2017-06-01
|
| Серии: | Медицинский совет |
| Предметы: | |
| Online-ссылка: | https://www.med-sovet.pro/jour/article/view/1894 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|